Wednesday, April 17, 2019 Novel Antibody May Suppress HIV for Up to Four Months NIAID Researchers, International Collaborators Report Results of Small, Open-Label Study Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study of 29 volunteers indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV. The study was supported in part by NIAID and United Biopharma, Inc.